Efficacy of Convalescent Plasma Therapy in the Early Care of COVID-19 Patients. (PLASCOSSA)

This is an interventional treatment trial for COVID-19 focused on measuring SARS-CoV-2, COVID 19, Convalescent plasma Read More

Inclusion Criteria:

1. Age 18-90 years ;
2. COVID-19 confirmed case ;

3. Cases showing respiratory symptoms, checking at least one of the following criteria:

   1. Cough, dyspnea, respiratory rate > 24 breaths/min
   2. Oxygen saturation < 95% at rest in ambient air
   3. PaO2 < 70mmHg
   4. Scanographic pulmonary compatible with COVID in the absence of any other etiology

4. Risk of deterioration, checking at least one of the following comorbidity criteria :

   1. Chronic respiratory pathology
   2. Diabetes
   3. Cancer pathology
   4. Cardiovascular disease
   5. Chronic kidney failure
   6. Congenital or acquired immunodeficiency
   7. Cirrhosis at stage B
   8. Major sickle cell syndrome
   9. BMI > 30 kg/m2

OR one of the biological criteria :

1. D-dimer 1 µg/mL,
2. Lymphocytes < 0.8 G/L,
3. Ferritin > 300 µg/L,
4. Troponin I > 11 pg/mL or Troponin T > 24.8 pg/mL

Exclusion Criteria:

• Patients admitted in intensive care within the first 6 hours of hospital care,
• Patients after 10 days from the start of symptoms
• Age < 18 years and > 90 years
• Long-term oxygen-dependent patients (at home),
• Decompensated chronic cardiac, respiratory, urological pathology
• Patient refusing administration of blood products,
• Allergic reaction to plasma products,
• IgA deficiency,
• Contraindication to transfusion
• Ig transfusion within 30 days,
• Patient currently participating to another clinical trial,
• Pregnant women,
• No affiliated to the social security,
• Person deprived of liberty by a legal or administrative decision, person under guardianship